Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4666 AL 4680

Research progress on natural products in regulating the gut microbiota in Parkinson's disease

Jia Y, Zhang Y, Tai X, Zhao T, Zhang H, Zhou H.

Front Pharmacol. 2025 Sep 8;16:1667694. doi: 10.3389/fphar.2025.1667694. eCollection 2025.

Apathy in Neuropsychiatric Disorders: Clinical Characteristics, Neurobiological Mechanisms, and Therapeutic Strategies

Totuk O, Şahin S.

Behav Neurol. 2025 Sep 15;2025:3788122. doi: 10.1155/bn/3788122. eCollection 2025.

Virtual reality in Parkinson's disease: a systematic review and meta-analysis

Fernandes JVA, Figueiredo VLFA, Oliveira AB, Reis IA, Henrique GLD, da Silva EA.

Dement Neuropsychol. 2025 Sep 19;19:e20240257. doi: 10.1590/1980-5764-DN-2024-0257. eCollection 2025.

Beyond the brain: The colorectal impact of Parkinson's disease

Khan S, Gupta A, Agarwal A, Alam MA, Kanagala SG, Jain R.

J Parkinsons Dis. 2025 Dec;15(8):1337-1344. doi: 10.1177/1877718X251380261. Epub 2025 Sep 24.

Micro- and nanoscale biosensing technologies for early diagnosis of Parkinson's disease

Nikam T, Rana A, Saraf SA, Awasthi S.

Mikrochim Acta. 2025 Sep 24;192(10):691. doi: 10.1007/s00604-025-07505-2.

Artri King induced Cushing syndrome in an 82-year-old man

Choi S, Youn C, Yang V, Bax C, Bae G.

Dermatol Online J. 2025 Jun 15;31(3). doi: 10.5070/D331365365.

Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments

Xiang J, Tang J, Kang F, Ye J, Cui Y, Zhang Z, Wang J, Wu S, Ye K.

Neuron. 2025 Oct 1;113(19):3300-3302. doi: 10.1016/j.neuron.2025.09.015. Epub 2025 Sep 23.

The oral microbiome-redox-inflammation axis in neurodegeneration: mechanistic insights and therapeutic perspectives

Tien Vo TT, Tsai MH, Cheng CY, Wang YL, Lee WJ, Lee IT.

Biochem Pharmacol. 2025 Dec;242(Pt 3):117362. doi: 10.1016/j.bcp.2025.117362. Epub 2025 Sep 22.

New frontier for epilepsy treatment through targeting cellular senescence

Bello ST, Rafe MR, Huang F.

Prog Neuropsychopharmacol Biol Psychiatry. 2025 Oct 2;142:111506. doi: 10.1016/j.pnpbp.2025.111506. Epub 2025 Sep 22.

Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson's disease clinical trial

Martinez-Lemus JD, Molony DA, Suescun J, Tharp E, Thomas TS, Green C, Onuigbo C, Ritter R 3rd, Schiess MC.

Stem Cell Res Ther. 2025 Sep 24;16(1):493. doi: 10.1186/s13287-025-04577-y.

The relationship between orthostatic hypotension and cognitive impairment in Parkinson's disease: a systematic review and meta-analysis

Liu Y, Jiang Y, Wang J, Shi Y.

Front Med (Lausanne). 2025 Sep 9;12:1659043. doi: 10.3389/fmed.2025.1659043. eCollection 2025.

Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders

Alborghetti M, Barbieri MA, Nicoletti F, Spina E.

Expert Opin Drug Metab Toxicol. 2025 Oct;21(10):1169-1193. doi: 10.1080/17425255.2025.2566692. Epub 2025 Sep 26.

Prions and protein aggregates as pathogens, self-propagating structures, biomarkers, and therapeutic targets

Caughey B, Artikis E, Shoup D, Orrú CD, Alam P, Parveen S, King S, Soukup J, Hughson AG, Priola SA.

Microbiol Mol Biol Rev. 2025 Dec 18;89(4):e0000725. doi: 10.1128/mmbr.00007-25. Epub 2025 Sep 25.

Therapeutic Potential of Flavonoids in Parkinson's Disease

Pechlivani L, Giannakis A, Sioka C, Alexiou GA, Konitsiotis S, Kyritsis AP.

J Nutr. 2025 Nov;155(11):3618-3641. doi: 10.1016/j.tjnut.2025.09.022. Epub 2025 Sep 23.

Polypharmacy-induced serotonin syndrome revealing underlying neurocognitive impairment and cervical myelopathy

Shah J, Parsons A, Pathuri S, Lieberman J, Hatten-Powell C.

BMJ Case Rep. 2025 Sep 25;18(9):e267753. doi: 10.1136/bcr-2025-267753.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias